Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 400
- Registration Number
- NCT05925049
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 275
- Registration Number
- NCT05798520
- Locations
- 🇺🇸
Vanderbilt MS Center, Nashville, Tennessee, United States
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
A Study of Spinraza (Nusinersen) Exposure in Pregnant Women With Spinal Muscular Atrophy (SMA) Within Existing SMA Registries
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT05789758
- Locations
- 🇬🇧
St George's University NHS Foundation Trust, London, Greater London, United Kingdom
🇬🇧The Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 10500
- Registration Number
- NCT05767736
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Biogen
- Registration Number
- NCT05764122
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 34
- Registration Number
- NCT05701423
- Locations
- 🇩🇪
Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1178
- Registration Number
- NCT05688436
- Locations
- 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 908
- Registration Number
- NCT05658497
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
🇺🇸IQVIA US Office, Durham, North Carolina, United States
🇮🇪St Vincent's University Hospital, Dublin, Ireland
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT05658484
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Xiangya Hospital Central South University, Changsha, China
🇨🇳West China Hospital of Sichuan University, Chengdu City, China
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 19
- Registration Number
- NCT05655507
- Locations
- 🇺🇸
Sage Investigational Site, Cincinnati, Ohio, United States